ASX Penny Stocks To Watch In October 2026

As the Australian share market prepares to open higher, influenced by positive movements on Wall Street and concerns over bond yields, investors are keeping a close eye on potential opportunities. Despite the term 'penny stocks' feeling somewhat antiquated, these smaller or newer companies can still offer significant growth potential when backed by strong financials. This article will explore three penny stocks that stand out for their balance sheet strength and potential to uncover hidden value in today's market conditions.

Let's review some notable picks from our screened stocks.

Centaurus Metals (ASX:CTM)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Centaurus Metals Limited focuses on the exploration, evaluation, and development of mineral resource projects in Brazil, with a market cap of A$262.82 million.

Operations: Centaurus Metals Limited does not report any revenue segments.

Market Cap: A$262.82M

Centaurus Metals Limited, with a market cap of A$262.82 million, operates in the pre-revenue stage, focusing on mineral resource projects in Brazil. Despite being unprofitable, the company has reduced its losses by 9.2% annually over the past five years and maintains a stable cash position with short-term assets of A$18.4 million exceeding liabilities. Recently added to the S&P Global BMI Index, Centaurus is debt-free and boasts an experienced management team with an average tenure of 6.9 years. Earnings are forecast to grow significantly at 90% per year, although volatility remains high at 9%.

• Click to explore a detailed breakdown of our findings in Centaurus Metals' financial health report.
• Review our growth performance report to gain insights into Centaurus Metals' future.

Havilah Resources (ASX:HAV)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Havilah Resources Limited, with a market cap of A$276.10 million, is involved in the exploration and evaluation of mineral exploration tenements and mining leases in Australia.

Operations: Havilah Resources Limited has not reported any specific revenue segments.

Market Cap: A$276.1M

Havilah Resources Limited, with a market cap of A$276.10 million, is navigating the pre-revenue stage in its exploration efforts. The company is financially stable, having no debt and short-term assets of A$23.5 million surpassing both short and long-term liabilities. Its management team and board are experienced, with average tenures exceeding industry norms. Recently added to the S&P/ASX Emerging Companies Index and All Ordinaries Index, Havilah has commenced RC drilling at Brooks Dam in South Australia after delays due to weather conditions. This project targets significant mineralization potential within the Kalkaroo stratabound host horizon (K2 unit).

• Click here to discover the nuances of Havilah Resources with our detailed analytical financial health report.
• Understand Havilah Resources' track record by examining our performance history report.

Nyrada (ASX:NYR)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nyrada Inc. is a clinical-stage biotechnology company that develops small-molecule therapies for neuroprotection and cardioprotection in Australasia, with a market cap of A$129.99 million.

Operations: The company's revenue segment is focused on drug development, specifically targeting small molecules, generating A$2.01 million.

Market Cap: A$129.99M

Nyrada Inc., with a market cap of A$129.99 million, remains in the pre-revenue stage, focusing on small-molecule drug development for neuroprotection and cardioprotection. Despite being unprofitable with a net loss of A$6.56 million for the year ending June 30, 2026, it maintains financial stability with short-term assets of A$10.4 million exceeding liabilities and no debt burden. The company recently raised A$14 million through follow-on equity offerings to bolster its cash runway beyond one year. However, Nyrada's share price has been highly volatile over the past three months despite stable weekly volatility compared to Australian peers.

• Take a closer look at Nyrada's potential here in our financial health report.
• Learn about Nyrada's historical performance here.

Turning Ideas Into Actions

• Unlock more gems! Our ASX Penny Stocks screener has unearthed 396 more companies for you to explore.Click here to unveil our expertly curated list of 399 ASX Penny Stocks.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com